OncoMatch/Clinical Trials/NCT07101744
Iparomlimab and Tuvonralimab Combined With Nimotuzumab in Recurrent or Metastatic NPC After First-line Treatment Failure: A Single-arm Phase IIa Clinical Trial
Is NCT07101744 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Iparomlimab and Tuvonralimab for nasopharyngeal carcinoma (npc).
Treatment: Iparomlimab and Tuvonralimab — This study aims to preliminarily explore the efficacy and safety of Iparomlimab and Tuvonralimab in combination with Nimotuzumab for the treatment of recurrent/metastatic nasopharyngeal carcinoma (NPC). It is expected to investigate a novel therapeutic regimen with improved efficacy and enhanced safety for recurrent/metastatic NPC, thereby providing robust evidence-based medical support for the application of dual-target immune checkpoint inhibitors in nasopharyngeal carcinoma therapy
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: platinum-based chemotherapy (cisplatin) — first-line
Lab requirements
Blood counts
ANC ≥ 2.0 × 10^9/L, hemoglobin ≥ 9.0 g/dL, platelets ≥ 100 × 10^9/L
Kidney function
Serum creatinine < 1.5 × ULN
Liver function
Total bilirubin < 1.5 × ULN, ALT and AST < 1.5 × ULN
Cardiac function
No significant impairment of cardiac function
Laboratory test results within 7 days prior to enrollment meeting the following criteria: Hematology: Absolute neutrophil count (ANC) ≥ 2.0 × 10^9/L, hemoglobin (Hb) ≥ 9.0 g/dL, platelets (PLT) ≥ 100 × 10^9/L; Liver function: Total bilirubin < 1.5 × ULN, ALT and AST < 1.5 × ULN; Renal function: Serum creatinine < 1.5 × ULN. Significant impairment of cardiac, hepatic, pulmonary, renal, or bone marrow function [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07101744 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received platinum-based chemotherapy.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify